Who are ATI-502's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clozaril, full-dose olanzapine, Quetiapine or Risperidone + Aripiprazole, placebo with Clozapine, Trazodone + PAP therapy, Aripiprazole; Quetiapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ati-502.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ATI-502 — Competitive Intelligence Brief

ATI-502 (ATI-502) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor antagonist. Area: Neurology.

phase 2 Serotonin receptor antagonist 5-HT2A Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ATI-502 (ATI-502) — Aclaris Therapeutics, Inc.. ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ATI-502 TARGET	ATI-502	Aclaris Therapeutics, Inc.	phase 2	Serotonin receptor antagonist	5-HT2A
Clozaril	CLOZAPINE	Jazz Pharmaceuticals	marketed	Atypical Antipsychotic [EPC]	D2, 5-HT2A	1989-01-01
full-dose olanzapine	full-dose olanzapine	Kaohsiung Kai-Suan Psychiatric Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine or Risperidone + Aripiprazole	Quetiapine or Risperidone + Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
placebo with Clozapine	placebo with Clozapine	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Trazodone + PAP therapy	Trazodone + PAP therapy	VA Office of Research and Development	marketed	Serotonin antagonist and reuptake inhibitor (SARI) + mechanical ventilation device	Serotonin transporter (SERT); serotonin 5-HT2A receptor antagonism
Aripiprazole; Quetiapine	Aripiprazole; Quetiapine	Taichung Veterans General Hospital	marketed	Atypical antipsychotic combination	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-01 — Clozaril · 8057811 · Formulation · US

Sponsor landscape (Serotonin receptor antagonist class)

Addpharma Inc. · 2 drugs in this class
Shire · 2 drugs in this class
Gedeon Richter Plc. · 1 drug in this class
Geropharm · 1 drug in this class
H. Lundbeck A/S · 1 drug in this class
Infan Industria Quimica Farmaceutica Nacional · 1 drug in this class
Phytopharm Consulting Brazil · 1 drug in this class
Taisho Pharmaceutical Co., Ltd. · 1 drug in this class
Aclaris Therapeutics, Inc. · 1 drug in this class
Visirna Therapeutics HK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATI-502 — Competitive Intelligence Brief. https://druglandscape.com/ci/ati-502. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab